Literature DB >> 11431704

Mitotic recombination effects homozygosity for NF1 germline mutations in neurofibromas.

E Serra1, T Rosenbaum, M Nadal, U Winner, E Ars, X Estivill, C Lázaro.   

Abstract

Pure populations of neurofibroma-derived Schwann cells bearing both NF1 mutated alleles (NF1-/-) have been isolated from different neurofibromas showing loss of heterozygosity of nearly the entire 17q chromosome. By comparing molecular and fluorescent in situ hybridization analysis of these cells, we demonstrate mitotic recombination is the mechanism underlying this type of loss of heterozygosity leading to reduction to homozygosity of NF1 germline mutation.

Entities:  

Mesh:

Year:  2001        PMID: 11431704     DOI: 10.1038/90148

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  18 in total

1.  Mitotic recombination as evidence of alternative pathogenesis of gastrointestinal stromal tumours in neurofibromatosis type 1.

Authors:  Douglas R Stewart; Christopher L Corless; Brian P Rubin; Michael C Heinrich; Ludwine M Messiaen; Lisa J Kessler; Paul J Zhang; David G Brooks
Journal:  J Med Genet       Date:  2007-01       Impact factor: 6.318

2.  Analysis of NF1 somatic mutations in cutaneous neurofibromas from patients with high tumor burden.

Authors:  Laura Thomas; Lan Kluwe; Nadia Chuzhanova; Victor Mautner; Meena Upadhyaya
Journal:  Neurogenetics       Date:  2010-04-01       Impact factor: 2.660

Review 3.  Neurofibromatosis type 1-associated tumours: their somatic mutational spectrum and pathogenesis.

Authors:  Sebastian Laycock-van Spyk; Nick Thomas; David N Cooper; Meena Upadhyaya
Journal:  Hum Genomics       Date:  2011-10       Impact factor: 4.639

4.  Type 2 NF1 deletions are highly unusual by virtue of the absence of nonallelic homologous recombination hotspots and an apparent preference for female mitotic recombination.

Authors:  Katharina Steinmann; David N Cooper; Lan Kluwe; Nadia A Chuzhanova; Cornelia Senger; Eduard Serra; Conxi Lazaro; Montserrat Gilaberte; Katharina Wimmer; Viktor-Felix Mautner; Hildegard Kehrer-Sawatzki
Journal:  Am J Hum Genet       Date:  2007-10-31       Impact factor: 11.025

5.  Mitotic recombination and compound-heterozygous mutations are predominant NF1-inactivating mechanisms in children with juvenile myelomonocytic leukemia and neurofibromatosis type 1.

Authors:  Doris Steinemann; Larissa Arning; Inka Praulich; Manfred Stuhrmann; Henrik Hasle; Jan Stary; Brigitte Schlegelberger; Charlotte M Niemeyer; Christian Flotho
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

6.  A quantitative assessment of the burden and distribution of Lisch nodules in adults with neurofibromatosis type 1.

Authors:  Sean Boley; Jennifer L Sloan; Alexander Pemov; Douglas R Stewart
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-06-10       Impact factor: 4.799

7.  The 4q12 amplicon in malignant peripheral nerve sheath tumors: consequences on gene expression and implications for sunitinib treatment.

Authors:  Jan Zietsch; Nicolas Ziegenhagen; Frank L Heppner; David Reuss; Andreas von Deimling; Nikola Holtkamp
Journal:  PLoS One       Date:  2010-07-29       Impact factor: 3.240

8.  Role of TC21/R-Ras2 in enhanced migration of neurofibromin-deficient Schwann cells.

Authors:  Yuan Huang; Fatima Rangwala; Patricia C Fulkerson; Bo Ling; Erin Reed; Adrienne D Cox; John Kamholz; Nancy Ratner
Journal:  Oncogene       Date:  2004-01-15       Impact factor: 9.867

9.  The spectrum of somatic and germline NF1 mutations in NF1 patients with spinal neurofibromas.

Authors:  Meena Upadhyaya; Gill Spurlock; Lan Kluwe; Nadia Chuzhanova; Emma Bennett; Nick Thomas; Abhijit Guha; Victor Mautner
Journal:  Neurogenetics       Date:  2009-02-17       Impact factor: 2.660

10.  Somatic alterations of the NF1 gene in an NF1 individual with multiple benign tumours (internal and external) and malignant tumour types.

Authors:  Gill Spurlock; Siân Griffiths; Jeremy Uff; Meena Upadhyaya
Journal:  Fam Cancer       Date:  2007       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.